Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overactive Detrusor Clear all
Recruiting Not applicable Interventional

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women

NCT07209397
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant), Mixed Urinary Incontinence, Idiopathic Overactive Bladder With Urinary Incontinence, Idiopathic Overactive Bladder
Interventions
Detrusor nerve radiofrequency ablation, Simulated (sham) detrusor nerve radiofrequency ablation
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
22 Years to 80 Years · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 22, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation

NCT01850706
View directory record Official record
Conditions
Detrusor Overactivity
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 22, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

NCT01557244
View directory record Official record
Conditions
Urinary Bladder, Neurogenic
Interventions
Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin, Fesoterodine PR, Fesoterodine BIC 2 mg, Fesoterodine BIC 4 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
18
States / cities
Tucson, Arizona • Orange, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 22, 2026, 10:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

NCT00495053
View directory record Official record
Conditions
Overactive Bladder
Interventions
hMaxi-K, Placebo
Drug · Other
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Branford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 22, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

NCT00224029
View directory record Official record
Conditions
Detrusor Hyperreflexia
Interventions
Oxybutynin transdermal system
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Atlanta, Georgia • The Bronx, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2010 · Synced Sep 22, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Minimizing Pain During Office Intradetrussor Botox Injection

NCT04270526
View directory record Official record
Conditions
Overactive Bladder, Overactive Detrusor, Overactive Bladder Syndrome, Overactivity; Behavior, Urge Incontinence
Interventions
Bicarbonate protocol, Standard protocol
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 22, 2026, 10:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Botulin-A Toxin Instillations and Overactive Bladder

NCT00583219
View directory record Official record
Conditions
Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia
Interventions
Botulinum-A toxin, Dimethyl sulfoxide (DMSO)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 22, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

NCT01565694
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Solifenacin succinate
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Tarrytown, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 22, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional

Refractory Urge Incontinence and Botox Injections

NCT00373789
View directory record Official record
Conditions
Urinary Incontinence, Detrusor Overactivity, Urinary Urgency, Urge Urinary Incontinence
Interventions
Botulinum Toxin A, bladder detrusor muscle injection, Vehicle saline as placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 22, 2026, 10:15 AM EDT
Withdrawn Phase 2 Interventional

Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.

NCT00262496
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
Botox
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 22, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

NCT01852045
View directory record Official record
Conditions
Urinary Incontinence
Interventions
OnabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 22, 2026, 10:15 AM EDT
Not listed Phase 4 Interventional

Oral vs Intravesical Analgesia for Office Bladder Botox Injections

NCT03755089
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Detrusor Instability
Interventions
Phenazopyridine, Lidocaine 2% Injectable Solution
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Sep 22, 2026, 10:15 AM EDT
Recruiting Phase 2Phase 3 Interventional

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

NCT05491525
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 22, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

NCT03168828
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Trospium-Releasing Intravesical System (TAR-302-5018)
Drug
Lead sponsor
Taris Biomedical LLC
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Troy, Michigan • Charlotte, North Carolina • Virginia Beach, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 22, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia

NCT00605319
View directory record Official record
Conditions
Bladder Outlet Obstruction
Interventions
Toviaz (Fesoterodine)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 99 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 22, 2026, 10:15 AM EDT
Terminated Not applicable Interventional

Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder

NCT00805779
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
MagPro R30
Device
Lead sponsor
EMKinetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 22, 2026, 10:15 AM EDT
Terminated No phase listed Observational

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

NCT01099345
View directory record Official record
Conditions
Bladder Function
Interventions
cystometry (CMG), polysomnography (PSG)
Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Sep 22, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

NCT01600716
View directory record Official record
Conditions
Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
Interventions
OnabotulinumtoxinA, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mountlake Terrace, Washington
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 22, 2026, 10:15 AM EDT
Terminated Not applicable Interventional Results available

TENS Used for Pain Management During Office Cystoscopy Botox Injections

NCT04448171
View directory record Official record
Conditions
Overactive Bladder
Interventions
Active TENS, Sham TENS
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 22, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

NCT01192568
View directory record Official record
Conditions
Overactive Detrusor, Neurogenic Bladder
Interventions
Oxybutynin, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 16 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
10
States / cities
Loma Linda, California • Orange, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 22, 2026, 10:15 AM EDT